Introduction: Therapeutic plasma exchange (TPE) is considered a treatment option for steroid-refractory multiple sclerosis (MS) relapses. Our objective was to assess long-term clinical response to TPE in MS steroid-refractory exacerbations.
Methods: Retrospective study of relapsing remitting MS (RRMS) patients presenting intravenous methylprednisolone (IVMPS)-refractory relapses, who underwent TPE. Response to TPE was assessed at 1, 3, 6, 12 and 24-months post-treatment, and compared to a second group of RRMS patients with similar demographic and clinical characteristics presenting, IVMPS-refractory relapses but not treated with TPE. Multivariate regression analysis was used to assess potential predictors of significant clinical response.
Results: Between 2011 to 2020, a total of 23 RRMS patients were treated with TPE. Twenty-one patients not receiving the treatment served as controls. No differences in demographic or clinical characteristics, or predictors of clinical improvement after TPE were detected between groups. Seventy-eight percent of patients treated with TPE presented clinical improvement at 24 months. TPE-treated patients presented lower EDSS scores at 6 and at 24 months. Younger age, presence of gadolinium-enhancing lesions and TPE treatment were associated with better clinical outcomes. No life-threatening side effects were reported.
Conclusions: TPE is a safe and well tolerated procedure that decreases long-term disability in RRMS patients with IVMPS-refractory relapses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2021.103168 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-world data of serum neurofilament light chain in a large cohort of Egyptian multiple sclerosis patients: Hospital-based study.
Mult Scler Relat Disord
January 2025
Department of Neurology and Psychiatry, Faculty of Medicine Assiut University, Assiut, Egypt. Electronic address:
Background: Serum neurofilament light chain (sNFL) is a promising biomarker for neuroaxonal injury in multiple sclerosis (MS). Traditional clinical and radiological examinations often fail to capture the underlying neurodegeneration, particularly in the absence of clinical relapses or gadolinium-enhanced lesions. This study aims to assess sNFL levels in real-world MS patients who have no evidence of activity, to evaluate the potential of sNFL as a biomarker for smoldering-associated worsening (SAW).
View Article and Find Full Text PDFPositive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study.
Mult Scler
January 2025
Radiology Department, Shamir Medical Center, Tzrifin, Israel.
Background: Measuring brain volume changes over time is an objective and dependable surrogate marker for the pathological processes that damage the brain in relapsing-remitting multiple sclerosis (RRMS). These measures are particularly valuable for monitoring the long-term impact of immunomodulatory treatments such as cladribine.
Objectives: To evaluate the long-term impact of oral cladribine treatment on brain volume loss in patients with RRMS.
Effectiveness of Ocrelizumab on Disease Progression and Disability Status in Multiple Sclerosis Patients: A Two-Year Prospective Cohort Study.
J Clin Med
January 2025
Discipline of Neurology, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation and neurodegeneration. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has shown promise in reducing disease activity in MS patients. This prospective study aims to assess the effectiveness of ocrelizumab in reducing confirmed disability progression in patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) over a two-year period.
View Article and Find Full Text PDFClinical Characteristics of Early-Onset and Late-Onset Multiple Sclerosis in Patients from Lithuania.
Medicina (Kaunas)
January 2025
Department of Neurology, Faculty of Medicine, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Early-onset MS (EOMS) and late-onset MS (LOMS) differ in terms of symptom presentation, disease progression, and disability outcomes. This study aims to evaluate the clinical characteristics of patients with EOMS and LOMS in Lithuania. A retrospective analysis of patients' medical records was conducted at the Lithuanian University of Health Sciences, Kaunas Clinics Department of Neurology.
View Article and Find Full Text PDFPrognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis.
Biomedicines
December 2024
Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, Turkey.
The course of relapsing-remitting multiple sclerosis (RRMS) is highly variable and there is a lack of effective prognostic biomarkers. This study aimed to assess the potential prognostic value of the chemokines B lymphocyte chemoattractant molecule (CXCL13), eotaxin-1 (CCL11), and macrophage inflammatory protein 3-alpha (CCL20) in RRMS. Forty-two patients with MS were enrolled, along with 22 controls, 12 of the controls were idiopathic intracranial hypertension (IIH) patients, and 10 of the controls were other neurologic diseases (OND).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!